Tokyo, Japan, July 28, 2011 ---Teijin Pharma Limited, the core company of the Teijin Group's medical and pharmaceutical business, announced today the launch of febuxostat, a novel drug developed by Teijin Pharma for the treatment of hyperuricemia and gout, in Korea on July 18. SK Chemicals Co., Ltd., the febuxostat licensee in Korea, is marketing the product under the brand name FEBURIC.
Teijin Pharma signed an exclusive licensing agreement with SK Chemicals in July 2004 for the development and marketing of febuxostat in Korea. In June 2009, SK Chemicals received approval from the Korea Food and Drug Administration to market the drug in the country for treatment of chronic hyperuricemia in patients with gout.
Febuxostat already is marketed by licensees, Takeda Pharmaceuticals North America, Inc. and Takeda Canada, Inc. under the brand name ULORIC in the U.S. and Canada, respectively, and marketed by Menarini Group under the brand name ADENURIC in Europe including France, the U.K., Germany, Ireland, Italy, Greece, Austria, Spain and Cyprus. In May of this year, Teijin Pharma launched the drug in Japan under the brand name FEBURIC. Collaborative efforts with licensees in other markets such as China, Hong Kong, Taiwan, Mexico, the Caribbean and Middle East and North African (MENA) regions are aimed at launching the drug in these markets as well.
Discovered by Teijin Pharma in 1991, febuxostat is the world's first non-purine selective inhibitor of xanthine oxidase. It has a novel chemical structure completely different from that of allopurinol, which has been used for over 40 years as the standard treatment for hyperuricemia and gout. Febuxostat effectively lowers the level of uric acid in the blood of hyperuricemic patients to the recommended level, and is well tolerated without need for dose adjustment in patients suffering from mild to moderate renal impairment.
Teijin Pharma has positioned febuxostat as a global strategic product and expects to achieve global annual sales of over 100 billion yen for the drug in the foreseeable future.
About Teijin Pharma Limited
Teijin Pharma Limited, the core company of Teijin Group's medical and pharmaceuticals business, focuses on three key therapeutic areas: respiratory, bone/joint, and cardiovascular/metabolic diseases. Teijin Pharma has strong marketing positions, particularly in the respiratory and bone/joint areas, with pharmaceutical products as well as a home healthcare business, including home oxygen therapy. Teijin Pharma continues to enhance its presence worldwide through in-house R&D as well as in-licensing and out-licensing activities. www.teijin-pharma.co.jp/english/index.html
About the Teijin Group
Based in Tokyo and Osaka, Japan, Teijin is a global technology-driven group operating in eight main fields: aramid fibers, carbon fibers & composites, polyester fibers, plastics, films, medical & pharmaceuticals, fiber products marketing and IT businesses. Teijin Limited, the holding company for the Teijin Group, is listed on the Tokyo and Osaka stock exchanges. The group, comprising 150 companies and 17,542 employees worldwide, had consolidated sales of JPY 815.7 billion (USD 10.1 billion) and total assets of JPY 761.5 billion (USD 9.5 billion) in the fiscal year ending March 31, 2011.
For further information, please contact:
Public Relations & Investor Relations Office
Tel: +81-3-3506-4055 / Fax: +81-3-3506-4150